This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

LSX Europe
Life Science Fundraising & Investment
25-26 March 2026 - Main days, Lisbon Congress Centre, Lisbon, Portugal24 March 2026 - Pre-day forums (Life Science Companies only), FIL (Feira Internacional de Lisboa)
Tickets
Menu
Tickets
keyboard_arrow_right

Day Two - Western European Summer Time (WEST)

keyboard_arrow_leftSearch & Filter
search
Day Two - Western European Summer Time (WEST)
search
Showing 1 of 1 Streams
11:30 - 12:10
Global Hotbeds of Innovation: Where Will the Next Breakthroughs Come From?
  • Sascha Berger - Investment Director, NEOM
  • Ester Sklarsky - Principal, Sound Bioventures
  • Luka Nicin - VC Investor, Pace Ventures
  • Marc Dechamps - CEO, Bioxodes
  • Artemy Shumskiy - Senior Associate, LongeVC
  • Neill Moray Mackenzie - Partner and Entrepreneur in Residence, ArgoBio Studio
12:10 - 12:50
From Lab to Launch: How to Turn Academic Research into a Viable Biotech
  • Deborah Sterling - Director, Sterne Kessler
  • Martin Svorc - Director, Neurology & Immunology, Fertility Business Development, Merck KGaA
  • Laura Ferguson - Director, Platform Technologies Search and Evaluation, AstraZeneca
  • Danuta Gawel - Chief Research and Development Officer, Mavatar
  • Michel de Baar - Executive Director, Business Development, Europe, MSD
  • Stephanie Marrus - Founder, Redwood Innovation Advisors
Showing 1 of 1 Streams
14:00 - 14:50
Rare Diseases vs. Broad Indications: Where to Focus Early-Stage Innovation
  • Lori Badura - Head of Global Partnering Rare Disease & Neuroscience, IPSEN
  • Sten Sörensen - CEO, Cereno Scientific
  • Linda McGoldrick - International Independent Director and Board Chair, Alvotech and Member of Council, Ministry for Science and Innovation, Portugal
  • Gražina Mykolaitytė-Nielsen - CEO and Co-Founder, VUGENE
14:50 - 15:40
Next-Gen Modalities: Beyond Antibodies and Small Molecules
  • Christopher Church - Head of Technology Search & Evaluation, Biopharmaceuticals R&D, AstraZeneca
  • Hiro Usuda - Scouting & Transaction Lead, Astellas
  • Jonas Båtelson - CEO, Curacell
  • Cristiana Pires - CEO, Asgard Tx
  • Mike Ward - Global Head of Life Sciences & Healthcare Thought Leadrership, Clarivate
Day One - Pre-Day
NextDay Two Showcases
Filter
Streams
Clear
Formats
Choose Day